Lung Cancer | Specialty

Atezolizumab Combo Approved in Europe for Small Cell Lung Cancer

September 6th 2019

The European Commission has approved atezolizumab for use in combination with carboplatin and etoposide for the frontline treatment of adult patients with extensive-stage small cell lung cancer, according to Roche (Genentech) the developer of the PD-L1 inhibitor.

Novel Lung Cancer Therapy: Future Improvements and Challenges

September 6th 2019

MET as a Clinical Target in Lung Cancer

September 6th 2019

Expanding the NSCLC Armamentarium: IMpower131

September 6th 2019

Extensive-Stage SCLC: Potential in the CASPIAN Trial

September 6th 2019

Targeted Therapy for KRAS p.G12C NSCLC

September 6th 2019

Future Directions in Lung Cancer Management

September 6th 2019

Metastatic NSCLC: Interpreting Data From NEPTUNE

September 6th 2019

Updated Data in Stage IV NSCLC: CheckMate-227

September 6th 2019

LIBRETTO-001: Targeting RET Fusions in Advanced-Stage NSCLC

September 6th 2019

Advanced-Stage NSCLC: Overall Survival Data From FLAURA

September 6th 2019

Overview of Novel Therapy for Advanced-Stage NSCLC

September 6th 2019

Dr. Ramalingam on the Activity of Osimertinib Combinations in NSCLC

September 6th 2019

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses the activity of osimertinib (Tagrisso) in combination with other agents in EGFR-mutant non–small cell lung cancer (NSCLC).

Dr. Farago on Effectiveness of Single-Agent Lurbinectedin in SCLC

September 4th 2019

Anna F. Farago, MD, PhD, assistant professor of medicine at Harvard Medical School, discusses the phase II trial results using the marine-based drug lurbinectedin as a single agent treatment inpatients with small cell lung cancer.

Frontline Osimertinib Approved in China for EGFR+ NSCLC

September 4th 2019

China’s National Medical Products Administration has approved osimertinib for the frontline treatment of adult patients with locally-advanced or metastatic non–small cell lung cancer whose tumors harbor EGFR exon 19 deletions or exon 21 (L858R) substitutions.

FDA Delays Decision on Frontline Atezolizumab Plus Carboplatin/Nab-Paclitaxel in Nonsquamous NSCLC

August 31st 2019

The FDA has extended the review period for a supplemental biologics license application for atezolizumab for use in combination with carboplatin and nab-paclitaxel as a first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer who do not have EGFR or ALK aberrations.

Dr. Wakelee on First Trial to Combine Antiangiogenic Agents With Immunotherapy in NSCLC

August 30th 2019

Heather A. Wakelee, MD, medical oncologist, thoracic specialist, professor of medicine at Stanford University, discusses results from the phase III IMpower150 trial in non–small cell lung cancer.

Dr. Wakelee on Rationale to Explore Osimertinib With Concurrent Chemotherapy in EGFR-Mutant NSCLC

August 30th 2019

Heather A. Wakelee, MD, professor of medicine, Stanford University Medical Center, discusses the rationale to explore osimertinib (Tagrisso) in combination with concurrent chemotherapy in patient with EGFR-mutant non–small cell lung cancer.

Dr. Hart on Impact of Trilaciclib on Myelosuppression in Extensive-Stage SCLC

August 30th 2019

Lowell L. Hart, MD, FACP, scientific director of Clinical Research at Florida Cancer Specialists & Research Institute, and associate professor of Internal Medicine at Wake Forest School of Medicine, discusses the impact of trilaciclib on myelosuppression in patients with previously treated extensive-stage small cell lung cancer.

Dr. Kris on the RELAY Trial in EGFR+ NSCLC

August 30th 2019

Mark G. Kris, MD, discusses the RELAY trial, which was an international, double-blind, randomized phase III study examining erlotinib in combination with ramucirumab versus placebo in previously untreated patients with EGFR-mutant metastatic non-small cell lung cancer.